Augustine Asset Management Inc. Acquires 14,790 Shares of Novo Nordisk A/S $NVO

Augustine Asset Management Inc. boosted its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 74.5% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 34,632 shares of the company’s stock after acquiring an additional 14,790 shares during the quarter. Augustine Asset Management Inc.’s holdings in Novo Nordisk A/S were worth $1,922,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds also recently made changes to their positions in the company. Jennison Associates LLC boosted its stake in Novo Nordisk A/S by 0.3% during the second quarter. Jennison Associates LLC now owns 18,885,343 shares of the company’s stock worth $1,303,466,000 after acquiring an additional 63,341 shares in the last quarter. Loomis Sayles & Co. L P boosted its holdings in Novo Nordisk A/S by 1.5% in the 2nd quarter. Loomis Sayles & Co. L P now owns 12,576,031 shares of the company’s stock worth $867,998,000 after buying an additional 187,789 shares during the period. Kingstone Capital Partners Texas LLC boosted its position in shares of Novo Nordisk A/S by 301,443.6% during the second quarter. Kingstone Capital Partners Texas LLC now owns 10,005,216 shares of the company’s stock worth $690,560,000 after acquiring an additional 10,001,898 shares during the last quarter. Sustainable Growth Advisers LP raised its position in shares of Novo Nordisk A/S by 11.7% during the 2nd quarter. Sustainable Growth Advisers LP now owns 6,192,636 shares of the company’s stock valued at $427,416,000 after buying an additional 649,390 shares in the last quarter. Finally, State Street Corp raised its position in Novo Nordisk A/S by 0.8% in the 2nd quarter. State Street Corp now owns 6,047,683 shares of the company’s stock worth $418,231,000 after purchasing an additional 47,430 shares during the period. 11.54% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on the stock. BMO Capital Markets reissued a “market perform” rating on shares of Novo Nordisk A/S in a report on Tuesday, December 23rd. Hsbc Global Res lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a report on Monday, November 24th. Rothschild Redb raised shares of Novo Nordisk A/S from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, September 16th. Argus restated a “hold” rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. Finally, Morgan Stanley reiterated an “underweight” rating and set a $42.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, December 3rd. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, eleven have assigned a Hold rating and four have assigned a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Hold” and an average price target of $53.33.

Novo Nordisk A/S News Roundup

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: Wegovy pill is now broadly available across the U.S., giving patients a once‑daily oral GLP‑1 alternative to injectables and expanding addressable market and patient choice. This supports upside to near‑term retail adoption and long‑term obesity franchise growth. WSJ: Wegovy Pill Now Broadly Available
• Positive Sentiment: Novo is offering self‑pay pricing starting at $149/month for the Wegovy pill (1.5 mg starter), positioning it as one of the cheaper cash options to drive uptake among uninsured or self‑pay patients and speed scale. Lower cash price could translate to faster patient volume and fill rates. Reuters: Wegovy Pill $149/month
• Positive Sentiment: Distribution is extensive: Wegovy pills are reported available at 70,000+ U.S. pharmacies, through telehealth partners and NovoCare, increasing access and lowering friction to patient starts — a catalyst for faster revenue ramp if persistence is solid. PR Newswire: Broad Availability
• Positive Sentiment: Market reaction: coverage notes rival stocks (e.g., Lilly, Viking) moving lower on the pill’s arrival, implying competitive share gain for Novo and possible sector re‑rating tailwinds. MSN: Competitors’ Stocks Down
• Neutral Sentiment: Regulatory path outside the U.S.: the U.K. regulator is reviewing Novo’s Wegovy pill application and may decide by year‑end — a potential future revenue catalyst but uncertain timing. Reuters: UK Review
• Negative Sentiment: Corporate/communications risk: Reuters reports Novo’s U.S. head of public affairs has left the company, which could complicate stakeholder engagement as Novo pushes to revive U.S. momentum; investors should watch for execution and messaging gaps. Reuters: Public Affairs Head Leaves

Novo Nordisk A/S Price Performance

NVO opened at $55.21 on Tuesday. Novo Nordisk A/S has a 1 year low of $43.08 and a 1 year high of $93.80. The stock has a market capitalization of $246.49 billion, a PE ratio of 16.05 and a beta of 0.66. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.57 and a current ratio of 0.78. The company’s 50 day simple moving average is $49.13 and its 200 day simple moving average is $55.57.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, topping analysts’ consensus estimates of $0.77 by $0.25. The firm had revenue of $11.79 billion during the quarter, compared to analysts’ expectations of $11.98 billion. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%. As a group, sell-side analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.